Valeant Pharmaceuticals Says It Agrees to Acquire INova for $624 Million

Valeant Pharmaceuticals International Inc. (VRX) said it has signed an agreement to acquire iNova.

To contact the editor responsible for this story: Mike Millard at mmillard2@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.